Christopher J Record,Mariola Skorupinska,Matilde Laura,Alexander M Rossor,Davide Pareyson,Chiara Pisciotta,Shawna M E Feely,Thomas E Lloyd,Rita Horvath,Reza Sadjadi,David N Herrmann,Jun Li,David Walk,Sabrina W Yum,Richard A Lewis,John Day,Joshua Burns,Richard S Finkel,Mario A Saporta,Sindhu Ramchandren,Michael D Weiss,Gyula Acsadi,Vera Fridman,Francesco Muntoni,Roy Poh,James M Polke,Stephan Zuchner,Michael E Shy,Steven S Scherer,Mary M Reilly,Lisa Abreu,Kimberly A Anderson,Silvia Baratta,Debbie Berry,Julian Blake,Eleonora Cavalca,Kayla Cornett,Andrea Cortese,Gabrielle Donlevy,Amanda Dragon,Magdalena Dudziec,Katy Eichinger Tim Estilow,Valerie Ferment,Natalie Grant,Tiffany Grider,Emily Hyslop,Tara Jones,Nicole Kressin,Wendy Leon,Stefania Magri,Brett McCray,Manoj Menezes,Evelin Milev,Lindsey Parrott,Pooja Patel,Cláudia Brito Pires,Valeria Prada,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary Shy,Carly Siskind,Janet Sowden,Sydney Stork,Charlotte J Sumner,Franco Taroni,Simone Thomas,Jennifer Twachtman-Bassett,Nidia Villalpando,Dragan Vujovic,Julie Wells,Elizabeth Wood,Riccardo Zuccarino,for the Inherited Neuropathies Consortium - Rare Disease Clinical Research Network

Abstract:Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterised by progressive sensory and motor neuropathy with males affected more severely than females. Many reported GJB1 variants remain classified as variants of uncertain significance (VUS). In this large, international, multicentre study we prospectively collected demographic, clinical and genetic data on patients with CMT associated with GJB1 variants. Pathogenicity for each variant was defined using adapted American College of Medical Genetics criteria. Baseline and longitudinal analyses were conducted to study genotype-phenotype correlations, to calculate longitudinal change using the CMT Examination Score (CMTES), to compare males versus females, and pathogenic/likely pathogenic (P/LP) variants versus VUS. We present 387 patients from 295 families harbouring 154 variants in GJB1 . Of these, 319 patients (82.4%) were deemed to have P/LP variants, 65 had VUS (16.8%) and 3 benign variants (0.8%; excluded from analysis); an increased proportion of patients with P/LP variants compared with using ClinVar's classification (74.6%). Male patients (166/319, 52.0%, P/LP only) were more severely affected at baseline. Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline. Genotype-phenotype analysis suggested c.-17G>A produces the most severe phenotype of the five most common variants, and missense variants in the intracellular domain are less severe than other domains. Progression of disease was seen with increasing CMTES over time up to 8 years follow-up. Standard response mean (SRM), a measure of outcome responsiveness, peaked at 3 years with moderate responsiveness (change in CMTES (ΔCMTES) = 1.3 ± 2.6, p = 0.00016, SRM = 0.50). Males and females progressed similarly up to 8 years, but baseline regression analysis suggested that over a longer period, females progress more slowly. Progression was most pronounced for mild phenotypes (CMTES = 0-7; 3-year ΔCMTES = 2.3 ± 2.5, p = 0.001, SRM = 0.90). Enhanced variant interpretation has yielded an increased proportion of GJB1 variants classified as P/LP and will aid future variant interpretation in this gene. Baseline and longitudinal analysis of this large cohort of CMTX1 patients describes the natural history of the disease including the rate of progression; CMTES showed moderate responsiveness for the whole group at 3 years and higher responsiveness for the mild group at 3, 4 and 5 years. These results have implications for patient selection for upcoming clinical trials.

POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease.

[A Genotyping Study of 13 Cases of Early-Onset Charcot-Marie-Tooth Disease].

Mutation Analysis of Ganglioside-Induced Differentiation Associated Protein-1 Gene in Chinese Charcot-Marie-Tooth Disease

The characteristics of gene mutations in Chinese patients with Charcot-Marie-Tooth disease]

[Analysis of the Pathological Features and Gene Mutations of Chinese Patients with Charcot-Marie-Tooth Disease].

POLG1 mutations associated with progressive encephalopathy in childhood

A new POLG1 mutation with peo and severe axonal and demyelinating sensory-motor neuropathy

Clinical,pathological and Genetic Studies in a Chinese Charcot-Marie-Tooth Disease Type 2 Family

P.17.12 POLG mitochondrial myopathy presenting as a limb girdle syndrome

Biallelic variants in cause a mitochondrial disorder primarily manifesting as peripheral neuropathy

A new POLG1 mutation with peo and severe axonal and demyelinating sensory–motor neuropathy

One Multilocus Genomic Variation Is Responsible for a Severe Charcot-Marie-Tooth Axonal Form

A Novel Missense Mutation in Peripheral Myelin Protein-22 Causes Charcot-Marie-Tooth Disease

Biallelic variants in COX18 cause a mitochondrial disorder primarily manifesting as peripheral neuropathy

Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants

IGHMBP2 -Related Clinical and Genetic Features in a Cohort of Chinese Charcot–Marie–Tooth Disease Type 2 Patients

Five Chinese patients with mitochondrial diseases caused by POLG gene mutations

Similar Clinical, Pathological, and Genetic Features in Chinese Patients with Autosomal Recessive and Dominant Charcot–Marie–Tooth Disease Type 2K

Clinical and genetic features of Charcot-Marie-Tooth disease patients with IGHMBP2 mutations

Clinical, neurophysiological evaluation and genetic features of axonal Charcot–Marie–Tooth disease in a Chinese family

Clinical features of autosomal recessive Charcot-Marie-Tooth disease 2K